Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
105 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Rectal Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Rectal Cancer - Pipeline Review, H2 2014', provides an overview of the Rectal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rectal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Rectal Cancer Overview 7 Therapeutics Development 8 Pipeline Products for Rectal Cancer - Overview 8 Pipeline Products for Rectal Cancer - Comparative Analysis 9 Rectal Cancer - Therapeutics under Development by Companies 10 Rectal Cancer - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Rectal Cancer - Products under Development by Companies 14 Rectal Cancer - Companies Involved in Therapeutics Development 15 GlaxoSmithKline plc 15 Celltrion, Inc. 16 Hanwha Chemical Co., Ltd. 17 Eisai Co., Ltd. 18 Peregrine Pharmaceuticals, Inc. 19 Synta Pharmaceuticals Corp. 20 Nanobiotix 21 Cerulean Pharma, Inc. 22 Incuron, LLC 23 Karyopharm Therapeutics, Inc. 24 Akshaya Bio Inc. 25 AbbVie Inc. 26 Rectal Cancer - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 31 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 E-7820 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 CRLX-101 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ISOMC-091 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ganetespib - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 mepacrine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 bavituximab - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 veliparib - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 GSK-2256098 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 selinexor - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 HD-204 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 NBTX-IV - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 NBTXR-3 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 bevacizumab biosimilar - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Vaccine to Target MUC1 for Cancer - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Rectal Cancer - Recent Pipeline Updates 67 Rectal Cancer - Dormant Projects 100 Rectal Cancer - Product Development Milestones 101 Featured News & Press Releases 101 Mar 18, 2014: Cerulean Announces First Patient Dosed in Phase 1b/2 Trial of CRLX101 in Combination with Chemotherapy and Radiation in Neoadjuvant Rectal Cancer 101 Nov 03, 2012: Merck KGaA Ceases Supply Of Cancer Drug Erbitux To Greek Hospitals 102 Sep 06, 2012: NCCN Oncology Research Program Receives Funding From GSK To Evaluate Clinical Effectiveness Of Trametinib 102 Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy 103 Appendix 104 Methodology 104 Coverage 104 Secondary Research 104 Primary Research 104 Expert Panel Validation 104 Contact Us 105 Disclaimer 105
List of Tables Number of Products under Development for Rectal Cancer, H2 2014 8 Number of Products under Development for Rectal Cancer - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Rectal Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 15 Rectal Cancer - Pipeline by Celltrion, Inc., H2 2014 16 Rectal Cancer - Pipeline by Hanwha Chemical Co., Ltd., H2 2014 17 Rectal Cancer - Pipeline by Eisai Co., Ltd., H2 2014 18 Rectal Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 19 Rectal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 20 Rectal Cancer - Pipeline by Nanobiotix, H2 2014 21 Rectal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 22 Rectal Cancer - Pipeline by Incuron, LLC, H2 2014 23 Rectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 24 Rectal Cancer - Pipeline by Akshaya Bio Inc., H2 2014 25 Rectal Cancer - Pipeline by AbbVie Inc., H2 2014 26 Assessment by Monotherapy Products, H2 2014 27 Number of Products by Stage and Target, H2 2014 30 Number of Products by Stage and Mechanism of Action, H2 2014 33 Number of Products by Stage and Route of Administration, H2 2014 35 Number of Products by Stage and Molecule Type, H2 2014 37 Rectal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 67 Rectal Cancer - Dormant Projects, H2 2014 100
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.